Mubadala Bio and Marcyrl Group forge strategic alliance to localize women’s health and respiratory therapies
A transformative partnership brings comprehensive pharmaceutical solutions to the UAE, advancing reproductive healthcare and respiratory treatment access across the nation.
Mubadala Bio has entered into a significant strategic partnership with Marcyrl Pharmaceutical Industries, an accord that promises to elevate healthcare provision across the United Arab Emirates through the localization of an extensive portfolio of women’s health, fertility and respiratory therapeutic products. The agreement was formalized at the Future Health Summit in Abu Dhabi, undersigned by Dr. Essam Mohamed, Group Chief Executive Officer of Mubadala Bio, and Dr. George Saad, Chief Executive Officer of Marcyrl Group.
This partnership represents a substantial commitment to advancing women’s healthcare throughout the nation. The women’s health and fertility portfolio encompasses a comprehensive range of medicines designed to support women through pivotal stages of their reproductive journey, from the pursuit of fertility through pregnancy and childbirth, extending to the treatment of prevalent gynaecological and hormonal conditions. The respiratory component of this collaboration addresses both acute and chronic respiratory conditions through an array of delivery mechanisms, including metered dose inhalers, dry powder inhalers, nebulization solutions and nasal sprays.
The localization and distribution of these combined portfolios within the UAE marks a meaningful progression in pharmaceutical self sufficiency. Dr. Mohamed articulated the strategic significance of this endeavour, emphasising that localizing pharmaceutical products remains integral to constructing a resilient life sciences ecosystem within the nation. He highlighted women’s health as a priority therapy area for Mubadala Bio, noting that the partnership facilitates the localization of a comprehensive medicinal portfolio whilst broadening access to essential treatments throughout the UAE.
Dr. Saad underscored the partnership’s importance as a pivotal advancement in expanding access to essential medicines across the UAE and the broader Gulf Cooperation Council region. He emphasised the synergistic potential of combining Marcyrl Group’s substantial manufacturing expertise in women’s health, fertility and respiratory care with Mubadala Bio’s established regional platform, a collaboration that will advance localization initiatives, fortify healthcare resilience and enhance patient access to quality therapeutics.
The agreement reinforces Mubadala Bio’s continuing endeavours to strengthen indigenous pharmaceutical capabilities, broaden access to priority therapies, and contribute meaningfully to the development of a comprehensive and integrated life sciences ecosystem throughout the United Arab Emirates. As the partnership progresses, additional products are anticipated to be incorporated into the portfolio, further enriching the therapeutic landscape available to patients across the nation.
Source: WAM
On Simply Luxury: Mubadala